Digestive Health Formulation 4 for Microbiota Balance and Gut Resilience

Product Overview

AMILI Probiotics Formulation 4, designated the Digestive Health formulation, delivers the highest colony-forming unit count in the AMILI precision probiotics range at 15 billion CFU per capsule. This formulation addresses the foundational layer of gut health — microbial diversity, mucosal barrier integrity, and digestive function — through a five-strain consortium anchored by Limosilactobacillus reuteri. L. reuteri is among the most extensively studied probiotic organisms in gastroenterology, with over 170 published clinical trials documenting its effects on gastrointestinal motility, pathogen inhibition via reuterin production, and intestinal epithelial barrier reinforcement.

Developed by AMILI Pte Ltd using strain selection informed by Asia's largest multi-ethnic gut microbiome reference database (AMILI BioCloud), Formulation 4 is calibrated for the digestive health challenges prevalent in Southeast Asian populations, including functional dyspepsia, irregular bowel habits, and antibiotic-associated microbiome disruption. The elevated 15 billion CFU dosage reflects clinical trial protocols for digestive health endpoints, where higher organism counts are associated with more consistent therapeutic responses. Delayed-release vegetarian capsules ensure organism viability through gastric acid transit, delivering viable bacteria to the colonic environment where they can establish colonisation and exert localised anti-inflammatory effects.

Specifications

Clinical Indications and Key Applications

• Functional gastrointestinal symptom management including bloating, irregular bowel habits, abdominal discomfort, and functional dyspepsia in adults
• Post-antibiotic microbiome restoration and recolonisation following broad-spectrum antimicrobial therapy disrupting commensal gut bacteria
• Gut barrier integrity reinforcement for individuals with increased intestinal permeability markers or chronic low-grade gastrointestinal inflammation
• Traveller's digestive health support for individuals exposed to novel microbial environments, unfamiliar dietary patterns, and water source changes
• Recommended formulation for individuals with AMILI Enhanced Gut Microbiome Test results indicating reduced microbial diversity, depleted Lactobacillus populations, or elevated pathobiont abundance
• Adjunctive digestive support for patients undergoing dietary interventions including elimination diets, low-FODMAP protocols, or therapeutic dietary transitions

Frequently Asked Questions

Why does Formulation 4 contain a higher CFU count than other AMILI formulations?

Formulation 4 delivers 15 billion CFU per capsule compared to 9 billion (Formulation 1) and 12 billion (Formulations 2 and 3) because clinical trial evidence for digestive health endpoints consistently demonstrates dose-dependent responses. A meta-analysis published in the American Journal of Gastroenterology analysing probiotic interventions for functional gastrointestinal disorders found that formulations delivering 10 billion CFU or higher produced statistically significant improvements in global symptom scores, while lower doses showed inconsistent effects. The elevated count in Formulation 4 also compensates for organism attrition during gastrointestinal transit, ensuring therapeutic colony counts reach the colon.

What makes Limosilactobacillus reuteri the lead strain for digestive health?

L. reuteri is one of the most extensively characterised probiotic organisms in gastroenterology, with unique antimicrobial properties derived from its production of reuterin (3-hydroxypropionaldehyde), a broad-spectrum antimicrobial compound active against gram-positive and gram-negative pathogens. L. reuteri has also demonstrated the ability to modulate gastrointestinal motility through enteric nervous system interactions, reduce visceral pain perception, and strengthen tight junction protein expression in the intestinal epithelium. The World Gastroenterology Organisation (WGO) Global Guidelines list L. reuteri among recommended probiotic strains for multiple gastrointestinal indications.

Can Formulation 4 be used during antibiotic treatment?

Probiotic supplementation during antibiotic therapy is supported by clinical evidence, with a Cochrane systematic review demonstrating that concurrent probiotic use reduces antibiotic-associated diarrhoea incidence by approximately 42%. When taking Formulation 4 alongside antibiotics, a minimum 2-hour separation between antibiotic and probiotic doses is recommended to reduce direct antimicrobial exposure to the probiotic organisms. Supplementation should continue for at least 2-4 weeks after completing the antibiotic course to support microbiome recovery. Healthcare providers in Singapore should consider individual patient factors including antibiotic class, treatment duration, and patient history when advising on concurrent probiotic use.

How does this formulation compare to generic digestive health probiotics available in pharmacies?

AMILI Formulation 4 differs from mass-market digestive probiotics in three key aspects: strain selection based on Asian population microbiome data rather than Western reference databases; delayed-release capsule technology ensuring colonic delivery rather than standard capsules where organisms are exposed to gastric acid; and a higher 15 billion CFU count reflecting clinical trial dosing protocols. Additionally, AMILI products are developed by a microbiome science company with proprietary metagenomic sequencing capabilities, and can be paired with the AMILI Enhanced Gut Microbiome Test for personalised baseline assessment and progress monitoring.

Where can healthcare practitioners in Singapore procure AMILI Formulation 4?

AMILI Probiotics Formulation 4 is distributed in Singapore through EMIS (Essential Medical International Supplies Pte Ltd). Gastroenterology clinics, integrative medicine practices, functional medicine practitioners, and wellness centres can arrange institutional procurement with volume pricing. The product is classified as a health supplement under the Health Sciences Authority (HSA) Singapore regulatory framework. EMIS provides Certificates of Analysis, batch traceability documentation, and dedicated account management for healthcare institution partners requiring regulatory compliance documentation.